The STEP Program: Every Semaglutide Weight-Loss Trial

The STEP program established semaglutide 2.4 mg as the leading pharmacologic weight-loss therapy. Walking through every major STEP trial and what it proved.

The STEP program is the family of pivotal clinical trials that established semaglutide 2.4 mg (Wegovy) as an effective treatment for chronic weight management. Starting with STEP 1 in 2021 and extending through STEP HFpEF, STEP 9, STEP 10, and the ongoing STEP-related programs, the collective dataset is one of the most extensive pharmacologic weight-management evidence bases ever assembled. This review walks through the major trials and what each added to the clinical picture.

STEP 1: The Foundation

STEP 1 (Wilding et al, NEJM 2021) randomized 1,961 adults with overweight or obesity (BMI ≥30, or ≥27 with weight-related comorbidity) without type 2 diabetes to weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks, both arms receiving lifestyle intervention. Mean weight change was -14.9% with semaglutide vs -2.4% with placebo. Over two-thirds of semaglutide patients achieved ≥10% weight loss; over one-third achieved ≥15%; and roughly one in eight achieved ≥20%.

STEP 1 also included cardiometabolic secondary endpoints: semaglutide improved blood pressure, lipid parameters, glycemic indices, and inflammatory markers. Gastrointestinal adverse events were the primary tolerability issue, with nausea, diarrhea, and vomiting common in early titration but generally improving over time.

STEP 2 Through STEP 5: Filling Out the Evidence

STEP 4 is particularly important for clinical understanding: patients who discontinued semaglutide after the lead-in phase regained approximately two-thirds of lost weight within a year. This established that GLP-1 therapy for obesity is a chronic treatment, not a time-limited intervention, and has informed current clinical guidance on continuation.

STEP 6 Through STEP 8: Expanding Populations

STEP 6 examined East Asian populations and confirmed the weight-loss magnitude in a different demographic. STEP 7 focused on obesity in Black, Indigenous, and other underrepresented populations. STEP 8 compared semaglutide head-to-head with liraglutide, demonstrating substantial superiority. Each of these trials added confidence in the generalizability of semaglutide's weight-loss effect across populations and ensured the pivotal evidence base was not limited to the original STEP 1 demographic.

STEP HFpEF and STEP-Related Trials

STEP HFpEF examined semaglutide in patients with obesity-related heart failure with preserved ejection fraction, demonstrating meaningful improvements in symptoms, functional capacity, and quality of life. This led to follow-on investigations of semaglutide in broader heart failure populations and to the subsequent inclusion of GLP-1 receptor agonists in heart failure guidelines for obesity-phenotype patients. Related programs — STEP Teens (adolescents), STEP 9 (knee osteoarthritis pain), and STEP 10 (Medicare-aligned outcomes) — have continued to expand the evidence into specific clinical populations.

What the STEP Program Established

Pre-STEP, the pharmacologic anti-obesity landscape was characterized by medications producing 5-8% mean weight loss with modest clinical benefit. STEP 1 and its successors demonstrated that a 2-3x larger effect was achievable, and that the benefit extended beyond weight to cardiometabolic health. This evidence base was the foundation for Wegovy's approval, the subsequent cardiovascular approval from SELECT, the FLOW kidney indication, and the expanded Medicare coverage.

Comparing to the SURMOUNT Program

The analog for tirzepatide is the SURMOUNT program, which has produced similar or slightly larger weight-loss magnitudes. SURMOUNT-1 (analog to STEP 1) reported approximately 20.9% mean weight loss at top dose, and SURMOUNT-5 head-to-head showed the tirzepatide advantage quantitatively. For most clinical questions, the STEP and SURMOUNT programs are best viewed as parallel evidence bases establishing their respective drugs, with the two programs together defining the current clinical standard for pharmacologic anti-obesity therapy. See our SURMOUNT-5 fact check and SELECT review for the complementary evidence.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.